adUnits.push({
code: ‘Rpp_mundo_estados_unidos_Nota_Interna1’,
mediaTypes: {
banner: {
sizes: (navigator.userAgent.match(/iPhone|android|iPod/i)) ? [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100]] : [[300, 250], [320, 460], [320, 480], [320, 50], [300, 100], [320, 100], [635, 90]]
}
},
bids: [{
bidder: ‘appnexus’,
params: {
placementId: ‘14149971’
}
},{
bidder: ‘rubicon’,
params: {
accountId: ‘19264’,
siteId: ‘314342’,
zoneId: ‘1604128’
}
},{
bidder: ‘amx’,
params: {
tagId: ‘MTUybWVkaWEuY29t’
}
},{
bidder: ‘oftmedia’,
params: {
placementId: navigator.userAgent.match(/iPhone|android|iPod/i) ? ‘22617692’: ‘22617693’
}
}]
});
US Food and Drug Administration (USA)FDAin English) proposed to simplify the calendar vaccination vs COVID-19 and that the doses are annual, as is the case with the common flu.
In a series of documents published Monday on its website, the US regulator indicated that the majority of the population may only need an annual dose to protect themselves from the disease, regardless of what they received previously.
FDA indicates that young people who have not been exposed to COVID-19older or immunosuppressed people may need two annual doses.
The idea of this body would be to evaluate possible new variants of the virus circulating during the year and choose the one it thinks will prevail next fall to develop a vaccine, as is usually done with the flu.
FDA recommendation
In its documents, the agency advocates the creation of a single vaccine formulation instead of what has been done so far, with a combination of monovalent sera (used in vaccines against COVID-19 original and in the first reinforcement) and other polyvalent ones (reinforcements against omicrons).
“Simplification of vaccine formulation should reduce complexity, reduce vaccine administration errors due to the complexity of different vial presentations, and potentially increase vaccination compliance by providing clearer communication,” the FDA said in its writings.
Advisory Committee on Vaccines and Biologicals FDA, an independent body of scientists, will evaluate the future of the COVID-19 vaccine in the US this Thursday and vote on whether to uphold the regulatory body’s recommendations. (EFE)
Source: RPP
I’m a passionate and motivated journalist with a focus on world news. My experience spans across various media outlets, including Buna Times where I serve as an author. Over the years, I have become well-versed in researching and reporting on global topics, ranging from international politics to current events.